Overview and capabilities of Naobios
Naobios provides bioprocess development and contract manufacturing services for viral vaccines and viral vectors. The company was acquired by Clean Biologics on March 1st, 2019 and now supports clients for process development and the manufacture of preclinical and clinical batches.
In the newsSee all news
Clean Mails – September 2022
Naobios x GenSensor: a partnership for bioprocess optimization
Naobios and GenSensor, two renowned companies of the biopharma sector, have announced a partnership to further advance bioprocess optimization for clinical lots of viral vaccines and vectors. It will allow for enhanced bioprocesses and optimized scale-up.
Naobios delivers FluGen Inc’s M2SR influenza vaccine candidate for upcoming clinical trials
Naobios’ development work and GMP manufacturing of vaccine clinical batches enables FluGen to conduct its 2022 clinical trials in the United States.
Clean Mails – May 2022
GMP biomanufacturing in a BSL-3 suite
A GMP biomanufacturing expert, Naobios has worked with numerous viruses requiring specific biocontainment procedures. Our state-of-the-art BSL-3 suite welcome hazardous microbes used for the generation of virus-based therapeutic products.
Clean Biologics was born in 2018 from a fruitful alliance between Clean Cells and Archimed. Through this partnership, the group soon acquired and integrated CDMO Naobios to extend the service offer and to promote our future-oriented thinking. The expertise, transparency, progress and a human-centred view are at the core of our identity. Day after day, we use our knowledge and our skills to deliver high-quality services in innovative projects with an unwavering dynamism and commitment.
Over 15 Years
History in GMP and Process Development Activities
of 40 people